← Back to Search

Pharmacist-Led Access to Medications for Opioid Use Disorder (PLI-MOUD Trial)

N/A

Waitlist Available

Led By Meghan N Breckling, PharmD

Research Sponsored by University of Arkansas

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at month 6

Awards & highlights

PLI-MOUD Trial Summary

This trial looks at the impact of a pharmacist-led program to provide access to opioid use disorder meds & Narcan for those in carceral settings to reduce overdose risk post-release.

Who is the study for?

This trial is for individuals with opioid use disorder who are soon to be released from incarceration in Little Rock. They must plan to stay in the area, have no allergy to naloxone, and be able to perform physical tasks like rolling a person over. Participants need reliable phone access, contact information for follow-ups, and must understand English.Check my eligibility

What is being tested?

The study tests pharmacist-led interventions aimed at increasing access to medications that treat opioid addiction. It includes Narcan training for overdose response, motivational counseling, and referral programs post-release from carceral settings.See study design

What are the potential side effects?

While specific side effects aren't listed here, generally Narcan (naloxone) can cause withdrawal symptoms in people dependent on opioids. These may include body aches, fever, sweating, runny nose or sneezing.

PLI-MOUD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at month 6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at month 6

This trial's timeline: 3 weeks for screening, Varies for treatment, and at month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Opioid overdose training

Retention

PLI-MOUD Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Pharmacist Narcan TrainingExperimental Treatment1 Intervention

Pharmacist-led intervention

Group II: Brief Intervention and Referral to Treatment (BIRT)Experimental Treatment1 Intervention

BIRT intervention

Group III: Substance Use Counselor Narcan TrainingActive Control1 Intervention

Non-clinician intervention

Group IV: Standard Medication Counseling (SMC)Active Control1 Intervention

SMC intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor

486 Previous Clinical Trials

149,873 Total Patients Enrolled

Meghan N Breckling, PharmDPrincipal InvestigatorUAMS

Azizi Ray, PhD, PharmDPrincipal InvestigatorUAMS

Media Library

Pharmacist Narcan Training Clinical Trial Eligibility Overview. Trial Name: NCT05776823 — N/A

Opioid Use Disorder Research Study Groups: Pharmacist Narcan Training, Substance Use Counselor Narcan Training, Brief Intervention and Referral to Treatment (BIRT), Standard Medication Counseling (SMC)

Opioid Use Disorder Clinical Trial 2023: Pharmacist Narcan Training Highlights & Side Effects. Trial Name: NCT05776823 — N/A

Pharmacist Narcan Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05776823 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants being recruited for this experiment at the present time?

"Clinicaltrials.gov informs us that this clinical trial, which was first announced on the 5th of May 2023, is not currently enrolling patients. However, there are still a total of 564 other trials with open recruitment slots as we speak."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)

2023. "Pharmacist-Led Interventions to Increase Access to Medications for Opioid Use Disorders (PLI-MOUD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05776823.